IP Library › Granted Patent US 12,378,243
Granted Patent B2
US 12,378,243 · App. 18/437,502 · Granted Aug 5, 2025

Quinoline compounds as inhibitors of KRAS

Inventors: Qinda Ye (Claymont, DE); Matthew McCammant (West Chester, PA); Rocco Policarpo (Wilmington, DE); Artem Shvartsbart (Wilmington, DE); Wenyu Zhu (Wilmington, DE); Jeremy Roach (Philadelphia, PA); Gia Hoang (Wilmington, DE); Bin Hu (Garnet Valley, PA); Gencheng Li (Claymont, DE); Robert Susick (Wilmington, DE); Padmaja Polam (Kennett Square, PA); Fenglei Zhang (Berwyn, PA); Chao Qi (Wilmington, DE); Xiaozhao Wang (Mt. Laurel, NJ); Wenqing Yao (Wilmington, DE); Alexander Sokolsky (Wilmington, DE); Haolin Yin (Wilmington, DE); Le Zhao (Wilmington, DE); Peter Carlsen (Wilmington, DE)
Assignee: Incyte Corporation
C07D471/04A61K31/4745A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,378,243
App. No.
18/437,502
Filed
Feb 9, 2024
Granted
Aug 5, 2025
Kind
B2
Art Unit
1626
USPC
514/210.18
Abstract

Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Claims (49)

1. A method of inhibiting KRAS activity, said method comprising contacting a compound selected from

3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1R,3R,5R)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

methyl (1S,3R,5S)-3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate;

methyl (1R,3R,5R)-3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate;

3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-2-((1R,3R,5R)-2-(1-methylcyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1R,3R,5R)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-(1-hydroxyethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1R,3R,5R)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

or a pharmaceutically acceptable salt thereof;

with KRAS.

2. The method of claim 1 , wherein the contacting comprises administering the compound to a patient.

3. A method of treating a disease or disorder associated with activity of a KRAS protein harboring a G12D mutation, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from:

3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1R,3R,5R)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

methyl (1S,3R,5S)-3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate;

methyl (1R,3R,5R)-3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate;

3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-2-((1R,3R,5R)-2-(1-methylcyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1R,3R,5R)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-(1-hydroxyethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile; and

3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1R,3R,5R)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 , wherein the disease or disorder is a cancer, Alzheimer's disease, HIV, or tuberculosis.

5. The method of claim 4 , wherein the disease or disorder is a cancer selected from a carcinoma, a hematological cancer, a sarcoma, and glioblastoma.

6. The method of claim 5 , wherein the cancer is a hematological cancer selected from a myeloproliferative neoplasm, a myelodysplastic syndrome, chronic and juvenile myelomonocytic leukemia, acute myeloid leukemia, acute lymphocytic leukemia, and multiple myeloma.

7. The method of claim 5 , wherein the cancer is a carcinoma selected from pancreatic, colorectal, lung, bladder, gastric, esophageal, breast, head and neck, cervical, skin, and thyroid.

8. The method of claim 3 , wherein the disease or disorder is an immunological or inflammatory disorder.

9. The method of claim 8 , wherein the immunological or inflammatory disorder is Ras-associated lymphoproliferative disorder or juvenile myelomonocytic leukemia caused by somatic mutations of KRAS.

10. The method of claim 1 , wherein the compound is 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1R,3R,5R)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile, or a pharmaceutically acceptable salt thereof.

11. The method of claim 1 , wherein the compound is 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1R,3R,5R)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile.

12. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt of 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1R,3R,5R)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile.

13. The method of claim 3 , wherein the compound is 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1R,3R,5R)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile, or a pharmaceutically acceptable salt thereof.

14. The method of claim 3 , wherein the compound is 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1R,3R,5R)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile.

15. The method of claim 3 , wherein the compound is a pharmaceutically acceptable salt of 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1R,3R,5R)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile.

16. The method of claim 1 , wherein the compound is 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-2-((1R,3R,5R)-2-(1-methylcyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile, or a pharmaceutically acceptable salt thereof.

17. The method of claim 1 , wherein the compound is 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-2-((1R,3R,5R)-2-(1-methylcyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile.

18. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt of 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-2-((1R,3R,5R)-2-(1-methylcyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile.

19. The method of claim 3 , wherein the compound is 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-2-((1R,3R,5R)-2-(1-methylcyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile, or a pharmaceutically acceptable salt thereof.

20. The method of claim 3 , wherein the compound is 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-2-((1R,3R,5R)-2-(1-methylcyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile.

21. The method of claim 3 , wherein the compound is a pharmaceutically acceptable salt of 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-2-((1R,3R,5R)-2-(1-methylcyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile.

22. The method of claim 1 , wherein the compound is 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1R,3R,5R)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-(1-hydroxyethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile, or a pharmaceutically acceptable salt thereof.

23. The method of claim 1 , wherein the compound is 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1R,3R,5R)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-(1-hydroxyethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile.

24. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt of 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1R,3R,5R)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-(1-hydroxyethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile.

25. The method of claim 3 , wherein the compound is 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1R,3R,5R)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-(1-hydroxyethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile, or a pharmaceutically acceptable salt thereof.

26. The method of claim 3 , wherein the compound is 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1R,3R,5R)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-(1-hydroxyethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile.

27. The method of claim 3 , wherein the compound is a pharmaceutically acceptable salt of 3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1R,3R,5R)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-(1-hydroxyethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile.

28. The method of claim 3 , wherein the disease or disorder is a cancer characterized by a KRAS protein harboring a G12D mutation.

29. The method of claim 28 , wherein the cancer is pancreatic cancer.

30. The method of claim 29 , wherein the pancreatic cancer is pancreatic ductal adenocarcinoma.

31. The method of claim 28 , wherein the cancer is colorectal cancer.

32. The method of claim 31 , wherein the colorectal cancer is colorectal carcinoma.

33. The method of claim 28 , wherein the cancer is lung cancer.

34. The method of claim 33 , wherein the lung cancer is non-small cell lung cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2025
From: YE, QINDA; MCCAMMANT, MATTHEW; POLICARPO, ROCCO; SHVARTSBART, ARTEM; ZHU, WENYU; ROACH, JEREMY; HOANG, GIA; HU, BIN; LI, GENCHENG; SUSICK, ROBERT; POLAM, PADMAJA; ZHANG, FENGLEI; QI, CHAO; WANG, XIAOZHAO; YAO, WENQING; SOKOLSKY, ALEXANDER; YIN, HAOLIN; ZHAO, LE; CARLSEN, PETER
To: INCYTE CORPORATION
Reel/Frame 071679/0787 →
Continuity (6)
Division 18046303 · Oct 13, 2022
Provisional Application 63368563 · Jul 15, 2022
Provisional Application 63363270 · Apr 20, 2022
Provisional Application 63279464 · Nov 15, 2021
Provisional Application 63255610 · Oct 14, 2021
Related Publication 20240368152A1 · Nov 7, 2024
References Cited (168)
US 5051508A · Brown et al. · 1991 [cited by applicant]
US 5281608A · Skotnicki et al. · 1994 [cited by applicant]
US 5360799A · Bachy et al. · 1994 [cited by applicant]
US 5420135A · Brown et al. · 1995 [cited by applicant]
US 5626633A · Roschger · 1997 [cited by applicant]
US 7592453B2 · Kajino et al. · 2009 [cited by applicant]
US 7897609B2 · Niwas et al. · 2011 [cited by applicant]
US 8034802B2 · Averett · 2011 [cited by applicant]
US 8143270B2 · Kshirsagar et al. · 2012 [cited by applicant]
US 8158794B2 · Kshirsagar et al. · 2012 [cited by applicant]
US 8207187B2 · Beek et al. · 2012 [cited by applicant]
US 8241917B2 · Fan et al. · 2012 [cited by applicant]
US 8354405B2 · Garcia et al. · 2013 [cited by applicant]
US 8455491B2 · Puech et al. · 2013 [cited by applicant]
US 8513250B2 · Escaich et al. · 2013 [cited by applicant]
US 8546395B2 · Pacaud et al. · 2013 [cited by applicant]
US 8557984B2 · Bouillot et al. · 2013 [cited by applicant]
US 8563565B2 · Norimine et al. · 2013 [cited by applicant]
US 8637670B2 · Kumar et al. · 2014 [cited by applicant]
US 8658666B2 · Rice et al. · 2014 [cited by applicant]
US 8697744B2 · Bolea et al. · 2014 [cited by applicant]
US 8822448B2 · Kaizawa et al. · 2014 [cited by applicant]
US 8846710B2 · Kshirsagar et al. · 2014 [cited by applicant]
US 8895581B2 · McConnell et al. · 2014 [cited by applicant]
US 9045419B2 · Lee et al. · 2015 [cited by applicant]
US 9062046B2 · Kumar et al. · 2015 [cited by applicant]
US 9169246B2 · Benazet et al. · 2015 [cited by applicant]
US 9403769B2 · Chand et al. · 2016 [cited by applicant]
US 9550776B2 · Norimine et al. · 2017 [cited by applicant]
US 9573947B2 · Ozaki · 2017 [cited by applicant]
US 9694006B2 · Beck et al. · 2017 [cited by applicant]
US 9771327B2 · Zawistoski et al. · 2017 [cited by applicant]
US 9873694B2 · Lipford et al. · 2018 [cited by applicant]
US 9960359B2 · Hwang et al. · 2018 [cited by applicant]
US 10039753B2 · Coffman et al. · 2018 [cited by applicant]
US 10081637B2 · Yu et al. · 2018 [cited by applicant]
US 10208055B2 · Yu et al. · 2019 [cited by applicant]
US 10249826B2 · Ogiwara et al. · 2019 [cited by applicant]
US 10251870B2 · Prossnitz et al. · 2019 [cited by applicant]
US 10326084B2 · Ise et al. · 2019 [cited by applicant]
US 10351557B2 · Fortte et al. · 2019 [cited by applicant]
US 10544138B2 · Gray et al. · 2020 [cited by applicant]
US 11053240B2 · Li et al. · 2021 [cited by applicant]
US 11530218B2 · Zhao et al. · 2022 [cited by applicant]
US 20030149069A1 · Li et al. · 2003 [cited by applicant]
US 20040147747A1 · Diwu et al. · 2004 [cited by applicant]
US 20050136537A1 · Sinclair et al. · 2005 [cited by applicant]
US 20060025337A1 · Sinclair et al. · 2006 [cited by applicant]
US 20060084135A1 · Howitz et al. · 2006 [cited by applicant]
US 20060276393A1 · Milburn et al. · 2006 [cited by applicant]
US 20060276416A1 · Sinclair et al. · 2006 [cited by applicant]
US 20070149466A1 · Milburn et al. · 2007 [cited by applicant]
US 20070191379A1 · Abelman et al. · 2007 [cited by applicant]
US 20080174474A1 · Harris et al. · 2008 [cited by applicant]
US 20100120818A1 · Enderle · 2010 [cited by applicant]
US 20100167925A1 · Koradin et al. · 2010 [cited by applicant]
US 20110003776A1 · Snyder et al. · 2011 [cited by applicant]
US 20110230476A1 · Niu et al. · 2011 [cited by applicant]
US 20110312934A1 · Garcia et al. · 2011 [cited by applicant]
US 20120015953A1 · Beauregard et al. · 2012 [cited by applicant]
US 20120065187A1 · Borchardt et al. · 2012 [cited by applicant]
US 20130190314A1 · Chiang et al. · 2013 [cited by applicant]
US 20140084217A1 · Ohya et al. · 2014 [cited by applicant]
US 20140243286A1 · Arnold et al. · 2014 [cited by applicant]
US 20160264570A1 · McKew et al. · 2016 [cited by applicant]
US 20170197945A1 · Li et al. · 2017 [cited by applicant]
US 20170217960A1 · Ferguson · 2017 [cited by applicant]
US 20170294489A1 · Lim et al. · 2017 [cited by applicant]
US 20190088887A1 · Feldman et al. · 2019 [cited by applicant]
US 20190131544A1 · Park et al. · 2019 [cited by applicant]
US 20190177338A1 · Kettle et al. · 2019 [cited by applicant]
US 20210269434A1 · Wang et al. · 2021 [cited by applicant]
US 20210308123A1 · Zhang et al. · 2021 [cited by applicant]
US 20210317118A1 · Zhang et al. · 2021 [cited by applicant]
US 20210355121A1 · Zhu et al. · 2021 [cited by applicant]
US 20210355141A1 · Hoang et al. · 2021 [cited by applicant]
US 20220064188A1 · Carlsen et al. · 2022 [cited by applicant]
US 20220106309A1 · Huang et al. · 2022 [cited by applicant]
US 20220306633A1 · Qi et al. · 2022 [cited by applicant]
US 20220389033A1 · Sokolsky et al. · 2022 [cited by applicant]
US 20230056631A1 · Gan et al. · 2023 [cited by applicant]
US 20230114765A1 · Li et al. · 2023 [cited by applicant]
US 20230143938A1 · Zhu et al. · 2023 [cited by applicant]
US 20230144051A1 · Ye et al. · 2023 [cited by applicant]
US 20230151005A1 · Carlsen et al. · 2023 [cited by applicant]
US 20230174555A1 · Li et al. · 2023 [cited by applicant]
CN 102399218A · 2012 [cited by applicant]
CN 103012397B · 2017 [cited by applicant]
CN 108003153A · 2018 [cited by applicant]
EP 1142889A1 · 2001 [cited by applicant]
IN 2012MUM02281A · 2014 [cited by applicant]
WO WO1994014777A1 · 1994 [cited by applicant]
WO WO1996009304A1 · 1996 [cited by applicant]
WO WO1999067238A2 · 1999 [cited by applicant]
WO WO2000043397A1 · 2000 [cited by applicant]
WO WO2001042247A1 · 2001 [cited by applicant]
WO WO2002020489A2 · 2002 [cited by applicant]
WO WO2004067513A1 · 2004 [cited by applicant]
WO WO2008035356A2 · 2008 [cited by applicant]
WO WO2008056151A1 · 2008 [cited by applicant]
WO WO2008079139A1 · 2008 [cited by applicant]
WO WO2009010824A1 · 2009 [cited by applicant]
WO WO2009123967A1 · 2009 [cited by applicant]
WO WO2010049366A1 · 2010 [cited by applicant]
WO WO2010070238A1 · 2010 [cited by applicant]
WO WO2010130934A1 · 2010 [cited by applicant]
WO WO2010135571A1 · 2010 [cited by applicant]
WO WO2012011642A1 · 2012 [cited by applicant]
WO WO2012040924A1 · 2012 [cited by applicant]
WO WO2012041227A1 · 2012 [cited by applicant]
WO WO2012116623A1 · 2012 [cited by applicant]
WO WO2012154731A1 · 2012 [cited by applicant]
WO WO2013045400A1 · 2013 [cited by applicant]
WO WO2013059559A2 · 2013 [cited by applicant]
WO WO2013147431A1 · 2013 [cited by applicant]
WO WO2014050417A1 · 2014 [cited by applicant]
WO WO2014097866A1 · 2014 [cited by applicant]
WO WO2014142467A1 · 2014 [cited by applicant]
WO WO2016161361A1 · 2016 [cited by applicant]
WO WO2016168540A1 · 2016 [cited by applicant]
WO WO2016199943A1 · 2016 [cited by applicant]
WO WO2017058805A1 · 2017 [cited by applicant]
WO WO2017070293A1 · 2017 [cited by applicant]
WO WO2017092413A1 · 2017 [cited by applicant]
WO WO2018119183A2 · 2018 [cited by applicant]
WO WO2018217651A1 · 2018 [cited by applicant]
WO WO2018221545A1 · 2018 [cited by applicant]
WO WO2018221546A1 · 2018 [cited by applicant]
WO WO2018221550A1 · 2018 [cited by applicant]
WO WO2018221551A1 · 2018 [cited by applicant]
WO WO2019049024A1 · 2019 [cited by applicant]
WO WO2019150305A1 · 2019 [cited by applicant]
WO WO2019177971A1 · 2019 [cited by applicant]
WO WO2019194481A1 · 2019 [cited by applicant]
WO WO2019201283A1 · 2019 [cited by applicant]
WO WO2019209896A1 · 2019 [cited by applicant]
WO WO2019213516A1 · 2019 [cited by applicant]
WO WO2020051207A2 · 2020 [cited by applicant]
WO WO2021063346A1 · 2021 [cited by applicant]
WO WO2022037631A1 · 2022 [cited by applicant]
U.S. Appl. No. 18/491,224, filed Oct. 20, 2023, Xiaozhao Wang. [cited by applicant]
U.S. Appl. No. 17/153,065 / 2021-230162 A1 / U.S. Pat. No. 11,530,218, filed Jan. 20, 2021 / Jul. 29, 2021 Dec. 20, 2022, Le Zhao. [cited by applicant]
U.S. Appl. No. 18/052,347 / 2023-0192696 A1, filed Nov. 3, 2022 / Jun. 22, 2023, Le Zhao. [cited by applicant]
U.S. Appl. No. 18/464,575, filed Sep. 11, 2023, Wenyu Zhu. [cited by applicant]
U.S. Appl. No. 17/318,720 / 2021-0355141 A1 / U.S. Pat. No. 11,739,102, filed May 12, 2021 / Nov. 18, 2021 / Aug. 29, 2023, Gia Hoang. [cited by applicant]
U.S. Appl. No. 17/458,964 / 2022-0064188 A1, filed Aug. 27, 2021 / Mar. 3, 2022, Peter Carlsen. [cited by applicant]
U.S. Appl. No. 17/449,696 / 2022/0106309 A1 / U.S. Pat. No. 11,767,320, filed Oct. 1, 2021 / Apr. 7, 2022 / Sep. 26, 2023, Taisheng Huang. [cited by applicant]
U.S. Appl. No. 17/700,923 / 2022/0306633 A1, filed Mar. 22, 2022 / Sep. 29, 2022, Chao Qi. [cited by applicant]
U.S. Appl. No. 17/661,182 / 2022-0389033 A1, filed Apr. 28, 2022 / Dec. 8, 2022, Alexander Sokolsky. [cited by applicant]
U.S. Appl. No. 18/480,307, filed Oct. 3, 2023, Alexander Sokolsky. [cited by applicant]
U.S. Appl. No. 17/810,915 / 2023-0056631 A1, filed Jul. 6, 2022 / Feb. 23, 2023, Pei Gan. [cited by applicant]
U.S. Appl. No. 17/812,310 / 2023-0114765 A1, filed Jul. 13, 2022 / Apr. 13, 2023, Zhenwu Li. [cited by applicant]
U.S. Appl. No. 17/823,254 / 2023-0174555 A1, filed Aug. 30, 2022 Jun. 8, 2023, Gencheng Li. [cited by applicant]
U.S. Appl. No. 17/933,660 / 2023-0151005 A1, filed Sep. 20, 2022 / May 18, 2023, Peter Carlsen. [cited by applicant]
U.S. Appl. No. 17/937,106 / 2023-0143938 A1, filed Sep. 30, 2022 / May 11, 2023, Wenyu Zhu. [cited by applicant]
U.S. Appl. No. 18/046,303 / 2023-0144051 A1, filed Oct. 13, 2022 / May 11, 2023, Qinda Ye. [cited by applicant]
U.S. Appl. No. 18/437,502, filed Feb. 9, 2024, Qinda Ye. [cited by applicant]
U.S. Appl. No. 18/349,606, filed Jul. 10, 2023, Gencheng Li. [cited by applicant]
Bauer, R.A., “Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies”, [cited by applicant]
Chen et al., “Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics”, [cited by applicant]
Cox et al., “Drugging the undruggable Ras: mission impossible?”, [cited by applicant]
Fernandez-Medarde et al., “Ras in Cancer and Developmental Diseases”, [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/077350, mailed Nov. 24, 2022, 13 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/078048, mailed Feb. 9, 2023, 13 pages. [cited by applicant]
Korzeniecki et al., “Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway”, [cited by applicant]
Ostrem et al., “K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions”, [cited by applicant]
Written Opinion of the International Searching Authority for PCT/US2021/027513, dated Oct. 21, 2021, 6 pages. [cited by applicant]
Zhu et al., “Structure-based discovery of selective BRPF1 bromodomain inhibitors”, [cited by applicant]